________________________________________________________________________________ >48cc group was 90% vs 46% (chi square p =.001). ROC curve analysis of our oropharyngeal subgroup revealed similar results with a cut off of 48cc with AUC of 0.802 (0.677-0.927) and sensitivity / specificity of 86%/70%.The RR for the <48cc and >48cc group was 88% vs 40% (chi square p = .001). The likelihood of not responding increased by 1.8%% for 1cc increase in TTV for the entire cohort and by 2.4% for our oropharyngeal subgroup.
Material and Methods:
Thirty patients with newly diagnosed NPC treated with radical RT and Cisplatin-based chemotherapy underwent prePET and iPET. The median follow up was 26 months (range 8-66.9). AJCC staging included 12 patients in stage II, 8 in stage III and 10 in stage IV. The maximum standardised-uptake-value (SUVmax), metabolic-tumour-volume (MTV) and total-lesional-glycolysis (TLG) of primary tumour (PT), the index-node (IN) (defined as lymph node with highest TLG), total lymph nodes (TN) and combined primary tumour and nodal (PTN), and their % reductions in iPET were analysed, and results were correlated with 2-year loco-recurrence-free-survival (LRFS), regionalfailure-free-survival (RFFS), distant-metastatic-failure-freesurvival (DMFFS), disease-free-survival (DFS), and overallsurvival (OS), using Kaplan-Meier (KM) analysis. Optimal-cutoffs (OC) were derived from Receiver-Operating-Characteristic curves for the best combined sensitivity and specificity.
Results: For LRFS, the only statistically significant predictor was reduction in primary tumour MTV by >50% in iPET (95.2% vs 75.0%, p= 0.024). For other treatment outcomes, only nodal or combined PTN predicted treatment outcomes. The IN SUVmax (pre-PET OC= 10.45g/mL and iPET OC= 8.15g/mL) and TLG (pre-PET OC= 90g and iPET OC= 33.4g) provide the overall best predictor of outcome, with significant associations with RFFS (iPET only), DMFFS (prePET), DFS (prePET and iPET) and OS (prePET) 
Conclusion:
The metabolic parameters of prePET and iPET can provide complementary prognostic biomarkers of patient outcomes, These parameters may have a role in adaptive therapy for NPC, and identifying the best treatment strategy for precision individualised chemo-radiotherapy combinations. We have demonstrated IN to be a useful novel imaging biomarker for predicting all treatment outcomes, and offers additional potential advantage of ease of generation and reproducibility compared to TN or PTN. 
EP-1096 Prognostic value of pretreatment FDG-PET features in laryngeal cancer patients treated with RT R. Kabarriti

Material and Methods:
We identified 83 consecutive patients with laryngeal squamous cell carcinoma treated with definitive RT with available pretreatment PET/CT scans at our institution. Clinical variables related to disease and patient characteristics, treatment information, and clinical outcomes data were collected for each patient. Pretreatment PET/CT scans were used for image feature analysis of the primary tumor volume for each patient. Multiple statistical image features were computed, along with several measures related to the standardized uptake value (SUV). Redundant image features were excluded based on a strong correlation with parameters commonly reported as important such as metabolic tumor volume (MTV) and maximum SUV value (SUVmax). A LASSO procedure was applied to select appropriate variables to include in Cox proportional hazard models for local control (LC) progression-free survival (PFS) and overall survival (OS). The concordance index or "Cindex" was computed to evaluate the discriminative ability of each model, both on the training data set (apparent C-index) and using bootstrap cross-validation (bCV). Correction for S528 ESTRO 35 2016 _____________________________________________________________________________________________________ multiple testing in statistical analysis was done using the Benjamini-Hochberg method.
Results: With a median follow up of 34 months, the 3-year LC, PFS and OS (with 95% confidence intervals) were 64% (53% -75%), 51% (39% -62%) and 77% (67% -87%), respectively. No image features were significantly correlated with LC or PFS and adding image features to the clinical variables did not improve the performance of the Cox model in the bCV setting, as seen in Table 1 where the C-index is highlighted in bold if adding image features improved performance.
MTV was the image feature most closely related to OS and for OS the addition of image features did improve the predictive performance of the Cox model. Figure 1 shows the effect of dividing the patient population based on the statistically most important variables, where it is clear that Karnofsky performance score and MTV affect the OS.
Conclusion
Adding image features to complement clinical parameters was seen to improve the prognostic value for OS. Although no significant image features were found related to LC and PFS, we found that a smaller MTV was predictive of improved OS. Purpose or Objective: Among cancers of head and neck, hypopharyngeal cancers tend to have an aggressive clinical course. Chemoradiation has become the standard of care for patients who are candidates for an organ preservation strategy. IMRT planning has incorporated a simultaneous integrated boost (SIB-IMRT) in order to efficiently develop comprehensive radiation therapy plans and also potentially lessen treatment time and toxicity. Outcomes and toxicites of patients with hypopharyngeal cancers treated in a single institute with standard IMRT and SIB-IMRT schedules were analyzed retrospectively.
EP-1097 Comparison of outcomes and toxicities between IMRT and SIB-IMRT in cancers of hypopharynx
Material and Methods:
A total of 86 patients with hypopharyngeal squamous cell carcinomas were treated between September 2010 and December 2014. Among 44 patients who were treated using SIB-IMRT, 8 received neoadjuvant chemotherapy (NACT) and 42 received concurrent chemotherapy. Among 42 patients who were treated using IMRT with conventional fractionation (IMRT),16 received NACT and 40 received concurrent chemotherapy. The dose for SIB-IMRT group was 65 Gy in 30 fractions to gross and high risk disease and 54 Gy in 30 fractions to low-risk nodes. The dose in IMRT group was 66-70 Gy to gross disease, 60 Gy to high risk nodes and 50 Gy to low risk nodes in 1.8-2 Gy per fraction.
